CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
12.08
+0.58 (5.04%)
At close: Aug 13, 2025, 4:00 PM
11.90
-0.18 (-1.49%)
Pre-market: Aug 14, 2025, 9:14 AM EDT
CorMedix Revenue
CorMedix had revenue of $39.74M in the quarter ending June 30, 2025, with 4,829.40% growth. This brings the company's revenue in the last twelve months to $121.48M, up 14,970.29% year-over-year. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$121.48M
Revenue Growth
+14,970.29%
P/S Ratio
6.30
Revenue / Employee
$1,868,992
Employees
65
Market Cap
901.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.47M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CRMD News
- 5 days ago - CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - CorMedix to Buy Melinta Therapeutics for $300 Million - WSJ
- 7 days ago - Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire
- 7 days ago - CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings - GlobeNewsWire
- 7 days ago - Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - CorMedix Analyst Says Investors Could Be Further Rewarded - Benzinga
- 6 weeks ago - CorMedix Seems Significantly Undervalued - Seeking Alpha
- 6 weeks ago - Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga